TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global and United States Recombinant Vaccines Market Report & Forecast 2022-2028

Global and United States Recombinant Vaccines Market Report & Forecast 2022-2028

  • Category:Life Sciences
  • Published on : 08 October 2022
  • Pages :95
  • Formats:
  • Report Code:SMR-7422950
OfferClick for best price

Best Price: $3480

Recombinant Vaccines Market Size, Share 2022


Market Analysis and Insights: Global Recombinant Vaccines Market

The global Recombinant Vaccines market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recombinant Vaccines market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Recombinant Vaccines market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Recombinant Vaccines market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Recombinant Vaccines market.

Global Recombinant Vaccines Scope and Market Size

Recombinant Vaccines market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Recombinant Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Recombinant Vaccines market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type

Subunit Recombinant Vaccines

Attenuated Recombinant Vaccines

Vector Recombinant Vaccines

Segment by Application

Recombinant Human Vaccines

Animal Recombinant Vaccines

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

U.A.E

By Company

Merck & Co., Inc

Green Cross Corporation

Pfizer Inc.

Bayer AG

Sanofi S A.

Protein Science Corporation

GlaxoSmithKline Plc.

Novartis AG

Bharat Biotech

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Recombinant Vaccines product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Recombinant Vaccines, with price, sales, revenue, and global market share of Recombinant Vaccines from 2019 to 2022.

Chapter 3, the Recombinant Vaccines competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Recombinant Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Recombinant Vaccines market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Vaccines.

Chapter 13, 14, and 15, to describe Recombinant Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Recombinant Vaccines Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global and United States Recombinant Vaccines Market Report & Forecast 2022-2028
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 95 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Study Coverage
1.1 Recombinant Vaccines Product Introduction
1.2 Global Recombinant Vaccines Outlook 2017 VS 2022 VS 2028
1.2.1 Global Recombinant Vaccines Sales in US$ Million for the Year 2017-2028
1.2.2 Global Recombinant Vaccines Sales in Volume for the Year 2017-2028
1.3 United States Recombinant Vaccines Outlook 2017 VS 2022 VS 2028
1.3.1 United States Recombinant Vaccines Sales in US$ Million for the Year 2017-2028
1.3.2 United States Recombinant Vaccines Sales in Volume for the Year 2017-2028
1.4 Recombinant Vaccines Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Recombinant Vaccines in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Recombinant Vaccines Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Recombinant Vaccines Market Dynamics
1.5.1 Recombinant Vaccines Industry Trends
1.5.2 Recombinant Vaccines Market Drivers
1.5.3 Recombinant Vaccines Market Challenges
1.5.4 Recombinant Vaccines Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Recombinant Vaccines Market Segment by Type
2.1.1 Subunit Recombinant Vaccines
2.1.2 Attenuated Recombinant Vaccines
2.1.3 Vector Recombinant Vaccines
2.2 Global Recombinant Vaccines Market Size by Type
2.2.1 Global Recombinant Vaccines Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Recombinant Vaccines Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Recombinant Vaccines Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Recombinant Vaccines Market Size by Type
2.3.1 United States Recombinant Vaccines Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Recombinant Vaccines Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Recombinant Vaccines Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Recombinant Vaccines Market Segment by Application
3.1.1 Recombinant Human Vaccines
3.1.2 Animal Recombinant Vaccines
3.2 Global Recombinant Vaccines Market Size by Application
3.2.1 Global Recombinant Vaccines Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Recombinant Vaccines Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Recombinant Vaccines Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Recombinant Vaccines Market Size by Application
3.3.1 United States Recombinant Vaccines Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Recombinant Vaccines Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Recombinant Vaccines Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Recombinant Vaccines Competitor Landscape by Company
4.1 Global Recombinant Vaccines Market Size by Company
4.1.1 Top Global Recombinant Vaccines Manufacturers Ranked by Revenue (2021)
4.1.2 Global Recombinant Vaccines Revenue by Manufacturer (2017-2022)
4.1.3 Global Recombinant Vaccines Sales by Manufacturer (2017-2022)
4.1.4 Global Recombinant Vaccines Price by Manufacturer (2017-2022)
4.2 Global Recombinant Vaccines Concentration Ratio (CR)
4.2.1 Recombinant Vaccines Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Recombinant Vaccines in 2021
4.2.3 Global Recombinant Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Recombinant Vaccines Manufacturing Base Distribution, Product Type
4.3.1 Global Recombinant Vaccines Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Recombinant Vaccines Product Type
4.3.3 Date of International Manufacturers Enter into Recombinant Vaccines Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Recombinant Vaccines Market Size by Company
4.5.1 Top Recombinant Vaccines Players in United States, Ranked by Revenue (2021)
4.5.2 United States Recombinant Vaccines Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Recombinant Vaccines Sales by Players (2020, 2021 & 2022)
5 Global Recombinant Vaccines Market Size by Region
5.1 Global Recombinant Vaccines Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Recombinant Vaccines Market Size in Volume by Region (2017-2028)
5.2.1 Global Recombinant Vaccines Sales in Volume by Region: 2017-2022
5.2.2 Global Recombinant Vaccines Sales in Volume Forecast by Region (2023-2028)
5.3 Global Recombinant Vaccines Market Size in Value by Region (2017-2028)
5.3.1 Global Recombinant Vaccines Sales in Value by Region: 2017-2022
5.3.2 Global Recombinant Vaccines Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Recombinant Vaccines Market Size YoY Growth 2017-2028
6.1.2 North America Recombinant Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Recombinant Vaccines Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Recombinant Vaccines Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Recombinant Vaccines Market Size YoY Growth 2017-2028
6.3.2 Europe Recombinant Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Recombinant Vaccines Market Size YoY Growth 2017-2028
6.4.2 Latin America Recombinant Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Recombinant Vaccines Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Recombinant Vaccines Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Merck & Co., Inc
7.1.1 Merck & Co., Inc Corporation Information
7.1.2 Merck & Co., Inc Description and Business Overview
7.1.3 Merck & Co., Inc Recombinant Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.1.4 Merck & Co., Inc Recombinant Vaccines Products Offered
7.1.5 Merck & Co., Inc Recent Development
7.2 Green Cross Corporation
7.2.1 Green Cross Corporation Corporation Information
7.2.2 Green Cross Corporation Description and Business Overview
7.2.3 Green Cross Corporation Recombinant Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Green Cross Corporation Recombinant Vaccines Products Offered
7.2.5 Green Cross Corporation Recent Development
7.3 Pfizer Inc.
7.3.1 Pfizer Inc. Corporation Information
7.3.2 Pfizer Inc. Description and Business Overview
7.3.3 Pfizer Inc. Recombinant Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Pfizer Inc. Recombinant Vaccines Products Offered
7.3.5 Pfizer Inc. Recent Development
7.4 Bayer AG
7.4.1 Bayer AG Corporation Information
7.4.2 Bayer AG Description and Business Overview
7.4.3 Bayer AG Recombinant Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Bayer AG Recombinant Vaccines Products Offered
7.4.5 Bayer AG Recent Development
7.5 Sanofi S A.
7.5.1 Sanofi S A. Corporation Information
7.5.2 Sanofi S A. Description and Business Overview
7.5.3 Sanofi S A. Recombinant Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Sanofi S A. Recombinant Vaccines Products Offered
7.5.5 Sanofi S A. Recent Development
7.6 Protein Science Corporation
7.6.1 Protein Science Corporation Corporation Information
7.6.2 Protein Science Corporation Description and Business Overview
7.6.3 Protein Science Corporation Recombinant Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Protein Science Corporation Recombinant Vaccines Products Offered
7.6.5 Protein Science Corporation Recent Development
7.7 GlaxoSmithKline Plc.
7.7.1 GlaxoSmithKline Plc. Corporation Information
7.7.2 GlaxoSmithKline Plc. Description and Business Overview
7.7.3 GlaxoSmithKline Plc. Recombinant Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.7.4 GlaxoSmithKline Plc. Recombinant Vaccines Products Offered
7.7.5 GlaxoSmithKline Plc. Recent Development
7.8 Novartis AG
7.8.1 Novartis AG Corporation Information
7.8.2 Novartis AG Description and Business Overview
7.8.3 Novartis AG Recombinant Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.8.4 Novartis AG Recombinant Vaccines Products Offered
7.8.5 Novartis AG Recent Development
7.9 Bharat Biotech
7.9.1 Bharat Biotech Corporation Information
7.9.2 Bharat Biotech Description and Business Overview
7.9.3 Bharat Biotech Recombinant Vaccines Sales, Revenue and Gross Margin (2017-2022)
7.9.4 Bharat Biotech Recombinant Vaccines Products Offered
7.9.5 Bharat Biotech Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Recombinant Vaccines Industry Chain Analysis
8.2 Recombinant Vaccines Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Recombinant Vaccines Distributors
8.3 Recombinant Vaccines Production Mode & Process
8.4 Recombinant Vaccines Sales and Marketing
8.4.1 Recombinant Vaccines Sales Channels
8.4.2 Recombinant Vaccines Distributors
8.5 Recombinant Vaccines Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Recombinant Vaccines CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Recombinant Vaccines Market Trends
Table 3. Recombinant Vaccines Market Drivers
Table 4. Recombinant Vaccines Market Challenges
Table 5. Recombinant Vaccines Market Restraints
Table 6. Global Recombinant Vaccines Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Recombinant Vaccines Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Recombinant Vaccines Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Recombinant Vaccines Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Recombinant Vaccines Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Recombinant Vaccines Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Recombinant Vaccines Revenue Share by Manufacturer, 2017-2022
Table 13. Global Recombinant Vaccines Sales by Manufacturer, (K Units), 2017-2022
Table 14. Global Recombinant Vaccines Sales Share by Manufacturer, 2017-2022
Table 15. Global Recombinant Vaccines Price by Manufacturer (2017-2022) & (USD/Unit)
Table 16. Global Recombinant Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Recombinant Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Vaccines as of 2021)
Table 18. Top Players of Recombinant Vaccines in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Recombinant Vaccines Product Type
Table 20. Date of International Manufacturers Enter into Recombinant Vaccines Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Recombinant Vaccines Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Recombinant Vaccines Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Recombinant Vaccines Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Recombinant Vaccines Sales by Players, (K Units), 2020, 2021 & 2022
Table 26. United States Recombinant Vaccines Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Recombinant Vaccines Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Recombinant Vaccines Sales in Volume by Region (2017-2022) & (K Units)
Table 29. Global Recombinant Vaccines Sales in Volume Forecast by Region (2023-2028) & (K Units)
Table 30. Global Recombinant Vaccines Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Recombinant Vaccines Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Recombinant Vaccines Sales in Volume by Country (2017-2028) & (K Units)
Table 33. North America Recombinant Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Recombinant Vaccines Sales in Volume by Region (2017-2028) & (K Units)
Table 35. Asia Pacific Recombinant Vaccines Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Recombinant Vaccines Sales in Volume by Country (2017-2028) & (K Units)
Table 37. Europe Recombinant Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Recombinant Vaccines Sales in Volume by Country (2017-2028) & (K Units)
Table 39. Latin Americaa Recombinant Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Recombinant Vaccines Sales in Volume by Country (2017-2028) & (K Units)
Table 41. Middle East and Africa Recombinant Vaccines Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. Merck & Co., Inc Corporation Information
Table 43. Merck & Co., Inc Description and Business Overview
Table 44. Merck & Co., Inc Recombinant Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 45. Merck & Co., Inc Recombinant Vaccines Product
Table 46. Merck & Co., Inc Recent Development
Table 47. Green Cross Corporation Corporation Information
Table 48. Green Cross Corporation Description and Business Overview
Table 49. Green Cross Corporation Recombinant Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 50. Green Cross Corporation Product
Table 51. Green Cross Corporation Recent Development
Table 52. Pfizer Inc. Corporation Information
Table 53. Pfizer Inc. Description and Business Overview
Table 54. Pfizer Inc. Recombinant Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 55. Pfizer Inc. Product
Table 56. Pfizer Inc. Recent Development
Table 57. Bayer AG Corporation Information
Table 58. Bayer AG Description and Business Overview
Table 59. Bayer AG Recombinant Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 60. Bayer AG Product
Table 61. Bayer AG Recent Development
Table 62. Sanofi S A. Corporation Information
Table 63. Sanofi S A. Description and Business Overview
Table 64. Sanofi S A. Recombinant Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 65. Sanofi S A. Product
Table 66. Sanofi S A. Recent Development
Table 67. Protein Science Corporation Corporation Information
Table 68. Protein Science Corporation Description and Business Overview
Table 69. Protein Science Corporation Recombinant Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 70. Protein Science Corporation Product
Table 71. Protein Science Corporation Recent Development
Table 72. GlaxoSmithKline Plc. Corporation Information
Table 73. GlaxoSmithKline Plc. Description and Business Overview
Table 74. GlaxoSmithKline Plc. Recombinant Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 75. GlaxoSmithKline Plc. Product
Table 76. GlaxoSmithKline Plc. Recent Development
Table 77. Novartis AG Corporation Information
Table 78. Novartis AG Description and Business Overview
Table 79. Novartis AG Recombinant Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 80. Novartis AG Product
Table 81. Novartis AG Recent Development
Table 82. Bharat Biotech Corporation Information
Table 83. Bharat Biotech Description and Business Overview
Table 84. Bharat Biotech Recombinant Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 85. Bharat Biotech Product
Table 86. Bharat Biotech Recent Development
Table 87. Key Raw Materials Lists
Table 88. Raw Materials Key Suppliers Lists
Table 89. Recombinant Vaccines Customers List
Table 90. Recombinant Vaccines Distributors List
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Vaccines Product Picture
Figure 2. Global Recombinant Vaccines Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Recombinant Vaccines Market Size 2017-2028 (US$ Million)
Figure 4. Global Recombinant Vaccines Sales 2017-2028 (K Units)
Figure 5. United States Recombinant Vaccines Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Recombinant Vaccines Market Size 2017-2028 (US$ Million)
Figure 7. United States Recombinant Vaccines Sales 2017-2028 (K Units)
Figure 8. United States Recombinant Vaccines Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Recombinant Vaccines Market Share in Global, in Volume (K Units) 2017-2028
Figure 10. Recombinant Vaccines Report Years Considered
Figure 11. Product Picture of Subunit Recombinant Vaccines
Figure 12. Product Picture of Attenuated Recombinant Vaccines
Figure 13. Product Picture of Vector Recombinant Vaccines
Figure 14. Global Recombinant Vaccines Market Share by Type in 2022 & 2028
Figure 15. Global Recombinant Vaccines Sales in Value by Type (2017-2028) & (US$ Million)
Figure 16. Global Recombinant Vaccines Sales Market Share in Value by Type (2017-2028)
Figure 17. Global Recombinant Vaccines Sales by Type (2017-2028) & (K Units)
Figure 18. Global Recombinant Vaccines Sales Market Share in Volume by Type (2017-2028)
Figure 19. Global Recombinant Vaccines Price by Type (2017-2028) & (USD/Unit)
Figure 20. United States Recombinant Vaccines Market Share by Type in 2022 & 2028
Figure 21. United States Recombinant Vaccines Sales in Value by Type (2017-2028) & (US$ Million)
Figure 22. United States Recombinant Vaccines Sales Market Share in Value by Type (2017-2028)
Figure 23. United States Recombinant Vaccines Sales by Type (2017-2028) & (K Units)
Figure 24. United States Recombinant Vaccines Sales Market Share in Volume by Type (2017-2028)
Figure 25. United States Recombinant Vaccines Price by Type (2017-2028) & (USD/Unit)
Figure 26. Product Picture of Recombinant Human Vaccines
Figure 27. Product Picture of Animal Recombinant Vaccines
Figure 28. Global Recombinant Vaccines Market Share by Application in 2022 & 2028
Figure 29. Global Recombinant Vaccines Sales in Value by Application (2017-2028) & (US$ Million)
Figure 30. Global Recombinant Vaccines Sales Market Share in Value by Application (2017-2028)
Figure 31. Global Recombinant Vaccines Sales by Application (2017-2028) & (K Units)
Figure 32. Global Recombinant Vaccines Sales Market Share in Volume by Application (2017-2028)
Figure 33. Global Recombinant Vaccines Price by Application (2017-2028) & (USD/Unit)
Figure 34. United States Recombinant Vaccines Market Share by Application in 2022 & 2028
Figure 35. United States Recombinant Vaccines Sales in Value by Application (2017-2028) & (US$ Million)
Figure 36. United States Recombinant Vaccines Sales Market Share in Value by Application (2017-2028)
Figure 37. United States Recombinant Vaccines Sales by Application (2017-2028) & (K Units)
Figure 38. United States Recombinant Vaccines Sales Market Share in Volume by Application (2017-2028)
Figure 39. United States Recombinant Vaccines Price by Application (2017-2028) & (USD/Unit)
Figure 40. North America Recombinant Vaccines Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 41. North America Recombinant Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 42. U.S. Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 43. Canada Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 44. Europe Recombinant Vaccines Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 45. Europe Recombinant Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 46. Germany Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. France Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. U.K. Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. Italy Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. Russia Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 51. Asia-Pacific Recombinant Vaccines Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 52. Asia-Pacific Recombinant Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 53. China Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. Japan Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. South Korea Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. India Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Australia Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. Taiwan Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Indonesia Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Thailand Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Malaysia Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Philippines Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 63. Latin America Recombinant Vaccines Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 64. Latin America Recombinant Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 65. Mexico Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Brazil Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Argentina Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 68. Middle East & Africa Recombinant Vaccines Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 69. Middle East & Africa Recombinant Vaccines Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 70. Turkey Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. Saudi Arabia Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. U.A.E Recombinant Vaccines Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 73. Recombinant Vaccines Value Chain
Figure 74. Recombinant Vaccines Production Process
Figure 75. Channels of Distribution
Figure 76. Distributors Profiles
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount